Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MMP2 | P08253 | 1/20 | 0.31 |
| ▸ | ANPEP | P15144 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25708713 | 1.00 | TSHR (0.34) | TSHRSMN1; SMN2MMP2ANPEP | |
| SCHEMBL26806863 | 1.00 | TSHR (0.34) | TSHRSMN1; SMN2MMP2ANPEP | |
| SCHEMBL23345359 | 1.00 | TSHR (0.34) | TSHRSMN1; SMN2MMP2ANPEP | |
| SCHEMBL24597123 | 0.82 | SCN1A (0.33) | TSHRSMN1; SMN2 | |
| SCHEMBL25708712 | 0.76 | SMN1; SMN2 (0.38) | TSHRSMN1; SMN2 | |
| SCHEMBL23995714 | 0.75 | TSHR (0.32) | TSHRSMN1; SMN2 | |
| SCHEMBL23345228 | 0.74 | TSHR (0.32) | TSHRSMN1; SMN2 | |
| SCHEMBL23995713 | 0.74 | TSHR (0.32) | TSHRSMN1; SMN2 | |
| SCHEMBL23345231 | 0.74 | TSHR (0.32) | TSHRSMN1; SMN2 | |
| SCHEMBL26053978 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265090-A1 | QUINAZOLINE COMPOUND | MEDSHINE DISCOVERY INC. (CN) | 2023-08-24 | — | — | US | disclosed |
| US-20230265090-A1 | QUINAZOLINE COMPOUND | MEDSHINE DISCOVERY INC. (CN) | 2023-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265090-A1 | QUINAZOLINE COMPOUND | ABCG2, CYP3A7, ABL1 | TSHR 3976/4885SMN1; SMN2 2114/4885MMP2 2895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.